Originally published byEU-Startups
Alchemab Therapeutics, a London-based clinical-stage BioTech startup, has extended its Series A financing with €29.3 million (£25 million/$34 million) from the British Business Bank. This marks the bank’s largest investment in a life sciences company to date. This additional funding brings Alchemab’s total Series A investment to date to €127.8 million (£109 million). The company […]
The post Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
From Kickoff To First Concept: How To Turn Brand Strategy Into Visual Direction
17h ago
Slothful summer app lets you scroll simply by tilting your head
10h ago
Destructive Windows backdoor stuffs multiple wipers and ransomware code into a single package
13h ago
LisaFPGA brings Apple's magnificent misfire back in programmable logic
13h ago
New Lithuanian unicorn: Oxylabs ends bootstrapped streak after securing €113.6 million at €3.1 billion valuation
1d ago